Current Market Information

Last Trade Price (LTP) 32.70 Last Trade Date 17 October, 2026 Change 0.60 % Open Price 33.60 Day's Range 32.70 - 35.00     Total Trade 32 Total Volume 24660 Close Price 33.80 Yesterday Close Price 33.60 Market Capital in BDT (mn) 4461.539

Contact Information

Designation Name Mobile Number Email Chairman Khaleda Akhter Khan 01313011502 chairman@technodrugsltd.com MD Shah Jalal Uddin Ahmed 01711567568 md@technodrugsltd.com CFO M. M Ahsanul Kabir 01313011399 ahsan@technodrugsltd.com Company Secretary S. M. Abu Talha Siddik 01313011301 contact@technodrugsltd.com Office Address J K Tower 31 Segunbagicha Dhaka- 1000 Phone : 02-58316038,01322800600 Fax : Email : infotechnodrugsltd.com Website : https://www.technodrugsltd.com/ Factory Address Unit -1 Satirpara, Narsingdi- 1600

Basic Information

Authorized Capital in BDT* (mn) 2,000.00 Paid-up Capital in BDT* (mn) 1,319.98 Face Value 10 Paid up Share 131998188     Market Lot 1 Sector PHARMA & CHEMICALS Market Category A

Other Information

Listing Year 2024 Debut Trade Date 14 July, 2024 Type of Instrument Equity     52 Week's Range 27.00 - 50.00 Year End 30 June Reserve / Surplus(mn) 2094.41 Remarks TK. 487,437,890 Revaluation Reserve has been added to Reserve & Surplus. Note

Share Holding Percentage

Sponsor/Director Govt. Institute Foreign Public As on 30-Sep, 2026 62.71 0 4.87 0 32.42 As on 31-Aug, 2026 62.71 0 4.73 0 32.56 As on 31-Jul, 2026 62.71 0 8.3 0 28.99 As on 30-Jun, 2026 (year ended) 62.71 0 6.3 0 30.99     Remarks Note     Credit Rating Status Credit Rating Year Long Term Short Term Outlook Validity Date Credit Rating Company Apr 07, 2026 BBB ST-3 Stable Apr 06, 2027 Emerging Credit Rating Ltd Apr 07, 2025 BBB ST-3 Stable Apr 06, 2026 Emerging Credit Rating Ltd Apr 07, 2024 A- ST-3 Stable Apr 06, 2025 Emerging Credit Rating Ltd         Half Year End (HY) Information  202512 HY Net Turnover(mn)  1708.09 HY Net Profit after tax(mn)  115.12 HY EPS  0.87  AGM Information   AGM Date  24 December, 2025 Record Date  19 November, 2025 Dividend(%)  10.00(Cash Dividend for general shareholders excluding Sponsors and Directors-June 2025) Bonus Issue

   

Interim Financial Performance: 2026
Particulars	Unaudited / Audited
	Q1	Q2	Half Yearly	Q3	9 Months	Annual
	Ending on	Ending on	6 Months	Ending on		Ending on
	30-Sep-2025	31-Dec-2025	31-Dec-2025	31-Mar-2026		30-Jun-2026
Earnings Per Share (EPS)
Basic	0.470	0.400	0.870	0.310	1.180
Diluted*
Earnings Per Share (EPS) - continuing operations
Basic	0.470	0.400	0.870	0.310	1.180
Diluted*
Market price per share at period end

*As per BSEC Directive No. SEC/CMRRCD/2009-193/64, dated September 21, 2010.

*Note: For detail financial statements, please visit company’s website.

   

Financial Performance
Performance Year	Basic EPS Based On		Basic EPS (restated) Based On		Net Asset Value Per Share	Restated Net Asset Value Per Share	Net Profit After Tax(mn)		% Dividend	% Dividend Yield
	Continuous operations	Including Extra-Ordinary Income	Continuous operations	Including Extra-Ordinary Income			Continuous operations	Including Extra-Ordinary Income
2025	1.76	0	0	0	30.58	0	232.02	0	10%C	3.56
2024	2.94	0	0	0	33.5	0	280.6	0	12%C	0
2023	2.08	0	0	0	27.74	0	195.51	0		0

Financial Statements
Quarterly Financial Statement	https://www.technodrugsltd.com/
Price Sensitive Information	https://www.technodrugsltd.com/

Close Price and Traded Volume Graph
Click here to view 1 month graph	Click here to view 3 month graph	Click here to view 6 month graph
Form	To